QL2107 (pembrolizumab biosimilar) / Qilu Pharma - LARVOL DELTA

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov) - P3 | N=255 | Recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: Oct 2026 ➔ Jan 2026

pMMR • Trial initiation date • Endometrial Cancer • Oncology • Solid Tumor • TP53

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer (clinicaltrials.gov) - P3 | N=718 | Not yet recruiting | Sponsor: SWOG Cancer Research Network

New P3 trial • Clear Cell Renal Cell Carcinoma • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (clinicaltrials.gov) - P1 | N=59 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2025 ➔ Jan 2027 | Trial primary completion date: Dec 2025 ➔ May 2025

Platinum resistant • Trial completion date • Trial primary completion date • Colorectal Cancer • Cutaneous Melanoma • Genito-urinary Cancer • Melanoma • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma (clinicaltrials.gov) - P2 | N=36 | Suspended | Sponsor: Mayo Clinic | Not yet recruiting ➔ Suspended

Trial suspension • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Gliosarcoma • Oncology • Sarcoma • Solid Tumor

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Dec 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • CD4

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (clinicaltrials.gov) - P3 | N=1210 | Recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Dec 2025 ➔ Jan 2027 | Trial primary completion date: Dec 2025 ➔ Jan 2027

Trial completion date • Trial primary completion date • Tumor mutational burden • Lung Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • EGFR • PD-L1

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov) - P3 | N=255 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2026 ➔ Oct 2026

Enrollment open • pMMR • Trial initiation date • Endometrial Cancer • Oncology • Solid Tumor • TP53

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma (clinicaltrials.gov) - P1 | N=71 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | N=110 ➔ 71 | Trial completion date: Dec 2025 ➔ Jan 2027

Enrollment change • Trial completion date • Tumor mutational burden • Brain Cancer • Diffuse Intrinsic Pontine Glioma • Ependymoma • Genetic Disorders • Glioma • High Grade Glioma • Medulloblastoma • Oncology • Solid Tumor • PD-L1 • TMB

GI-102 Alone or in Combination With Pembrolizumab Before Surgery for the Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Mayo Clinic

New P2 trial • Anaplastic Astrocytoma • Astrocytoma • Brain Cancer • Glioblastoma • Gliosarcoma • Oncology • Sarcoma • Solid Tumor

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Roswell Park Cancer Institute | Initiation date: Nov 2025 ➔ Feb 2026

Trial initiation date • Tumor mutational burden • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • PD-L1

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov) - P3 | N=255 | Not yet recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: Dec 2025 ➔ Mar 2026

pMMR • Trial initiation date • Endometrial Cancer • Oncology • Solid Tumor

RECIPE-B1: Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: Mayo Clinic | N=50 ➔ 70

Enrollment change • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment (clinicaltrials.gov) - P2 | N=23 | Not yet recruiting | Sponsor: City of Hope Medical Center

New P2 trial • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

QLC5508-201: A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=444 | Recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P1/2 trial • Oncology • Solid Tumor

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (clinicaltrials.gov) - P2 | N=111 | Recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: Jun 2026 ➔ Nov 2025

Trial initiation date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

S1607: Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma (clinicaltrials.gov) - P2 | N=43 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Nov 2025 ➔ Nov 2026

Trial completion date • Tumor mutational burden • Cutaneous Melanoma • Melanoma • Oncology • Solid Tumor

SWOG S1801: A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma (clinicaltrials.gov) - P2 | N=313 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Oct 2025 ➔ Oct 2026

Trial completion date • Cutaneous Melanoma • Melanoma • Mucosal Melanoma • Oncology • Solid Tumor • CD4

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (clinicaltrials.gov) - P3 | N=336 | Recruiting | Sponsor: National Cancer Institute (NCI) | Initiation date: Jun 2026 ➔ Nov 2025

IO biomarker • Trial initiation date • Cervical Adenocarcinoma • Cervical Cancer • Cervical Squamous Cell Carcinoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • PD-L1

EA8231: A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (clinicaltrials.gov) - P3 | N=320 | Recruiting | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

An open-label, multicenter Phase Ib/II clinical study on the safety, tolerability, pharmacokinetics, and efficacy of QLC5508 injection combined therapy in patients with advanced solid tumors (ChiCTR) - P1/2 | N=414 | Not yet recruiting | Sponsor: Shanghai East Hospital; Qilu Pharmaceutical Co.

New P1/2 trial • Solid Tumor

KEYNOTE-868: Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) - P3 | N=813 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: May 2026 ➔ Sep 2026

dMMR • pMMR • Trial completion date • Carcinosarcoma • Endometrial Adenocarcinoma • Endometrial Cancer • Endometrial Serous Adenocarcinoma • Oncology • Sarcoma • Solid Tumor • Uterine Cancer • PD-L1

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: Roswell Park Cancer Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Tumor mutational burden • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Richter's Syndrome • PD-L1

Alliance A091605: Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma (clinicaltrials.gov) - P2 | N=9 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Merkel Cell Carcinoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • CD4

SWOG S2001: Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations (clinicaltrials.gov) - P2 | N=88 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Suspended ➔ Active, not recruiting

Enrollment closed • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • BRCA • BRCA1

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma (clinicaltrials.gov) - P1/2 | N=49 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Sep 2025 ➔ Sep 2026

Trial completion date • Malignant Pleural Mesothelioma • Mesothelioma • Oncology • Pleural Mesothelioma • Solid Tumor • MSLN • PD-L1